a public good project by the
Synthesis
Company
of California

© 2026

Eric Santoni‐Rugiu | doi.page

0 works0 citations0 h-index

Eric Santoni‐Rugiu

University of Copenhagen(DK)Copenhagen University Hospital(DK)Rigshospitalet(DK)

Publications by Year

Research Areas

Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Occupational and environmental lung diseases, Epigenetics and DNA Methylation, Lung Cancer Diagnosis and Treatment

Most-Cited Works

→ Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex(1999)283 cited
→ Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance(2019)199 cited
→ Involvement of Myc Activity in a G ₁ /S-Promoting Mechanism Parallel to the pRb/E2F Pathway(2000)163 cited
→ Transit-Amplifying Ductular (Oval) Cells and Their Hepatocytic Progeny Are Characterized by a Novel and Distinctive Expression of Delta-Like Protein/Preadipocyte Factor 1/Fetal Antigen 1(2004)142 cited
→ The Histone Methyltransferase and Putative Oncoprotein MMSET Is Overexpressed in a Large Variety of Human Tumors(2011)140 cited
→ Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution

(2021)

140 cited

→ PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab(2011)136 cited

Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha.(1998)

→ Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model.(1996)121 cited

Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha.(1996)